wikimedia
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
Graphs
1
Q41891577-ED0E5DCB-F9F2-44A3-AC2E-968DEB363022
Q41891577-ED0E5DCB-F9F2-44A3-AC2E-968DEB363022
BestRank
Statement
http://www.wikidata.org/entity/statement/Q41891577-ED0E5DCB-F9F2-44A3-AC2E-968DEB363022
Inhibition of epidermal growth factor receptor attenuates LPS-induced inflammation and acute lung injury in rats.
P2860
Q41891577-ED0E5DCB-F9F2-44A3-AC2E-968DEB363022
BestRank
Statement
http://www.wikidata.org/entity/statement/Q41891577-ED0E5DCB-F9F2-44A3-AC2E-968DEB363022
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
d7bf864c58c79206df58af9d807c01abae36f1a9
P2860
A phase 2 trial of dacomitinib (PF-00299804), an oral, irreversible pan-HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non-small cell lung cancer after failure of prior chemotherapy and erlotinib.